Takeda Settles $13.6 Million Kickback Case Over Antidepressant Trintellix

Breaking: Takeda to Pay $13.6 Million in Kickback Settlement

Japanese pharmaceutical giant Takeda has agreed to pay $13.6 million to resolve allegations that it illegally induced doctors to prescribe its antidepressant Trintellix by offering speaking fees and lavish meals, the U.S. Department of Justice announced today.

The settlement ends a probe into practices between January 2014 and October 2020 that allegedly violated the False Claims Act by causing Medicaid to submit false claims for the drug.

Alleged Scheme: Speaking Fees and High-End Dining

From early 2014 through late 2020, Takeda allegedly paid physicians speaking fees and treated them to expensive restaurant meals to boost prescriptions of Trintellix, a medication used to treat major depressive disorder.

Authorities said many doctors attended multiple programs on the same topic, receiving meals and drinks without any educational benefit—suggesting the events were purely promotional.

Government Statement: 'Patients Best Interests Must Be Paramount'

“This settlement demonstrates the continued commitment of my office to ensure that patients’ best interests remain paramount,” said Eric Grant, U.S. Attorney for the Eastern District of California.

“Prescribing decisions should not be influenced by drug companies’ payments or side perks made available to physicians,” Grant added in a statement announcing the settlement.

Background

The investigation was conducted by the U.S. Attorney’s Office for the Eastern District of California and the Department of Health and Human Services Office of Inspector General. Takeda, based in Tokyo, did not admit liability as part of the settlement but agreed to cooperate with ongoing reviews.

This case is part of a broader federal crackdown on pharmaceutical kickbacks, which authorities say inflate healthcare costs and compromise patient care. Similar settlements have involved other drugmakers in recent years.

What This Means

The settlement sends a warning to other pharmaceutical companies that using financial incentives to influence prescribing decisions will face severe penalties. For physicians, it reinforces the need to ensure that medical choices are based on clinical evidence, not perks.

Medicaid and other government healthcare programs stand to recover funds lost to fraudulent prescriptions, and patients may benefit from more transparent prescribing practices going forward.

Takeda has stated it will continue to focus on ethical marketing and compliance with federal laws. The company has not commented further on the specifics of the allegations.